{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:23:38Z","timestamp":1788168218869,"version":"build-2803163510"},"reference-count":5,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>This Editorial introduces the series How to manage thyroid diseases: from autoimmunity to malignancy Special Issue: https:\/\/www.drugsincontext.com\/special_issues\/how-to-manage-thyroid-diseases-from-autoimmunity-to-malignancy<\/jats:p>","DOI":"10.7573\/dic.2026-7-10","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:07:17Z","timestamp":1788167237000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Management of thyroid disorders: from autoimmunity to malignancy \u2013 novel insights from precision medicine"],"prefix":"10.7573","author":[{"given":"Katerina","family":"Saltiki","sequence":"first","affiliation":[{"name":"National and Kapodistrian University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoris","family":"Effraimidis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04v4g9h31","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Thessaly"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","unstructured":"1.\tKarapanou O, Saltiki K, Markantes GK, Kasotas A, Michalaki M, Effraimidis G. How to manage autoimmune hyperthyroidism (Graves\u2019 disease): from differential diagnosis to emerging immunological therapies. Drugs Context. 2026;15:dic.2026-4-10. https:\/\/doi.org\/10.7573\/dic.2026-4-10"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tMarkantes GK, Effraimidis G, Karapanou O, Saltiki K, Michalaki M. How to manage thyroid eye disease: recent advances \u2014 a narrative review. Drugs Context. 2026;15:dic.2026-4-5. https:\/\/doi.org\/10.7573\/dic.2026-4-5","DOI":"10.1530\/EC-25-0796"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tEffraimidis G, Kasotas A, Markantes GK, Karapanou O, Saltiki K, Michalaki M. How to manage subacute thyroiditis. Drugs Context. 2026;15:dic.2026-4-6. https:\/\/doi.org\/10.7573\/dic.2026-4-6","DOI":"10.1530\/ETJ-25-0385"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tKarapanou O, Effraimidis G, Michalaki M, Saltiki K. How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. Drugs Context. 2026;15:dic.2026-4-4. https:\/\/doi.org\/10.7573\/dic.2026-4-4","DOI":"10.1530\/EC-25-0796"},{"key":"ref4","unstructured":"5.\tSaltiki K, Karapanou O, Michalaki M, Effraimidis G. How to manage medullary thyroid carcinoma: current treatment strategies. Drugs Context. 2026;15:dic.2026-4-3. https:\/\/doi.org\/10.7573\/dic.2026-4-3"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/08\/dic.2026-7-10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:07:19Z","timestamp":1788167239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/management-of-thyroid-disorders-from-autoimmunity-to-malignancy-novel-insights-from-precision-medicine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-7-10","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"dic.2026-7-10"}}